FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
ENTA Financial Statements
Year
2024
2023
2022
2021
Current Assets
299.85M
422.79M
311.71M
319.02M
Cash & Short Term Investments
248.19M
369.91M
249.23M
244M
Cash And Cash Equivalents
37.23M
85.39M
43.99M
57.21M
Short Term Investments
210.95M
284.52M
205.24M
186.8M
Net Receivables
6.65M
39.62M
49.04M
60.83M
Inventory
0
0
0
-37.26M
Other Current Assets
45.02M
13.26M
13.45M
14.19M
Non-Current Assets
76.8M
39.48M
63.7M
119.77M
Property, Plant & Equipment
73.35M
34.71M
29.75M
10.65M
Goodwill And Intangible Assets
0
0
-5.18M
-2.07M
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
29.29M
108.42M
Tax Assets
0
0
5.18M
2.07M
Other Non-Current Assets
3.45M
4.77M
4.66M
700k
Other Assets
0
0
0
0
Total Assets
376.65M
462.27M
375.41M
438.79M
-
-
-
-
Current Liabilities
57.53M
62.79M
29.83M
36.17M
Accounts Payable
8M
4.1M
6M
9.54M
Short Term Debt
3.05M
5.28M
5.78M
8.41M
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
0
Other Current Liabilities
46.48M
53.41M
18.05M
18.23M
Total Current Liabilities
57.53M
62.79M
29.83M
36.17M
Total Non-Current Liabilities
190.3M
182.75M
24.25M
3.19M
Long-Term Debt
53.94M
21.24M
22.37M
1.13M
Deferred Revenue
0
0
-5.18M
-2.07M
Deferred Taxes Liabilities
0
0
5.18M
2.07M
Other Non Current liabilities
136.36M
161.51M
1.88M
2.06M
Total Liabilities
247.84M
245.54M
54.08M
39.36M
Other Liabilities
0
0
0
0
Stockholders Equity
128.81M
216.74M
321.33M
399.43M
Common Stock
212k
211k
208k
202k
Retained Earnings
-323.04M
-207M
-73.18M
48.58M
Accumulated Other Comprehensive Income/Loss
302k
-1.17M
-3.72M
-382k
Other Shareholders Equity
451.34M
424.69M
398.03M
351.03M
Total Liabilities and Stockholders Equity
376.65M
462.27M
375.41M
438.79M
All figures are in USD.
